224 related articles for article (PubMed ID: 19671673)
1. Functional role of cell surface CUB domain-containing protein 1 in tumor cell dissemination.
Deryugina EI; Conn EM; Wortmann A; Partridge JJ; Kupriyanova TA; Ardi VC; Hooper JD; Quigley JP
Mol Cancer Res; 2009 Aug; 7(8):1197-211. PubMed ID: 19671673
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of tumor metastasis: functional immune modulation of the CUB domain containing protein 1.
Fukuchi K; Steiniger SC; Deryugina E; Liu Y; Lowery CA; Gloeckner C; Zhou B; Kaufmann GF; Quigley JP; Janda KD
Mol Pharm; 2010 Feb; 7(1):245-53. PubMed ID: 19916495
[TBL] [Abstract][Full Text] [Related]
3. In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated β1 integrin and induction of FAK/PI3K/Akt motility signaling.
Casar B; Rimann I; Kato H; Shattil SJ; Quigley JP; Deryugina EI
Oncogene; 2014 Jan; 33(2):255-68. PubMed ID: 23208492
[TBL] [Abstract][Full Text] [Related]
4. Blocking of CDCP1 cleavage in vivo prevents Akt-dependent survival and inhibits metastatic colonization through PARP1-mediated apoptosis of cancer cells.
Casar B; He Y; Iconomou M; Hooper JD; Quigley JP; Deryugina EI
Oncogene; 2012 Aug; 31(35):3924-38. PubMed ID: 22179830
[TBL] [Abstract][Full Text] [Related]
5. CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis.
Liu H; Ong SE; Badu-Nkansah K; Schindler J; White FM; Hynes RO
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1379-84. PubMed ID: 21220330
[TBL] [Abstract][Full Text] [Related]
6. Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen.
Hooper JD; Zijlstra A; Aimes RT; Liang H; Claassen GF; Tarin D; Testa JE; Quigley JP
Oncogene; 2003 Mar; 22(12):1783-94. PubMed ID: 12660814
[TBL] [Abstract][Full Text] [Related]
7. Targeting CUB domain-containing protein 1 with a monoclonal antibody inhibits metastasis in a prostate cancer model.
Siva AC; Wild MA; Kirkland RE; Nolan MJ; Lin B; Maruyama T; Yantiri-Wernimont F; Frederickson S; Bowdish KS; Xin H
Cancer Res; 2008 May; 68(10):3759-66. PubMed ID: 18483259
[TBL] [Abstract][Full Text] [Related]
8. KAI1 suppresses HIF-1α and VEGF expression by blocking CDCP1-enhanced Src activation in prostate cancer.
Park JJ; Jin YB; Lee YJ; Lee JS; Lee YS; Ko YG; Lee M
BMC Cancer; 2012 Mar; 12():81. PubMed ID: 22390300
[TBL] [Abstract][Full Text] [Related]
9. Regulation of inside-out β1-integrin activation by CDCP1.
Pollan SG; Huang F; Sperger JM; Lang JM; Morrissey C; Cress AE; Chu CY; Bhowmick NA; You S; Freeman MR; Spassov DS; Moasser MM; Carter WG; Satapathy SR; Shah K; Knudsen BS
Oncogene; 2018 May; 37(21):2817-2836. PubMed ID: 29511352
[TBL] [Abstract][Full Text] [Related]
10. CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma.
Uekita T; Jia L; Narisawa-Saito M; Yokota J; Kiyono T; Sakai R
Mol Cell Biol; 2007 Nov; 27(21):7649-60. PubMed ID: 17785447
[TBL] [Abstract][Full Text] [Related]
11. The tyrosine phosphatase SHP2 associates with CUB domain-containing protein-1 (CDCP1), regulating its expression at the cell surface in a phosphorylation-dependent manner.
Gandji LY; Proust R; Larue L; Gesbert F
PLoS One; 2015; 10(4):e0123472. PubMed ID: 25876044
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic Ras/ERK signaling activates CDCP1 to promote tumor invasion and metastasis.
Uekita T; Fujii S; Miyazawa Y; Iwakawa R; Narisawa-Saito M; Nakashima K; Tsuta K; Tsuda H; Kiyono T; Yokota J; Sakai R
Mol Cancer Res; 2014 Oct; 12(10):1449-59. PubMed ID: 24939643
[TBL] [Abstract][Full Text] [Related]
13. The SRC-associated protein CUB Domain-Containing Protein-1 regulates adhesion and motility.
Benes CH; Poulogiannis G; Cantley LC; Soltoff SP
Oncogene; 2012 Feb; 31(5):653-63. PubMed ID: 21725358
[TBL] [Abstract][Full Text] [Related]
14. Suppression of autophagy by CUB domain-containing protein 1 signaling is essential for anchorage-independent survival of lung cancer cells.
Uekita T; Fujii S; Miyazawa Y; Hashiguchi A; Abe H; Sakamoto M; Sakai R
Cancer Sci; 2013 Jul; 104(7):865-70. PubMed ID: 23510015
[TBL] [Abstract][Full Text] [Related]
15. CDCP1 identifies a broad spectrum of normal and malignant stem/progenitor cell subsets of hematopoietic and nonhematopoietic origin.
Bühring HJ; Kuçi S; Conze T; Rathke G; Bartolović K; Grünebach F; Scherl-Mostageer M; Brümmendorf TH; Schweifer N; Lammers R
Stem Cells; 2004; 22(3):334-43. PubMed ID: 15153610
[TBL] [Abstract][Full Text] [Related]
16. Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.
He Y; Wu AC; Harrington BS; Davies CM; Wallace SJ; Adams MN; Palmer JS; Roche DK; Hollier BG; Westbrook TF; Hamidi H; Konecny GE; Winterhoff B; Chetty NP; Crandon AJ; Oliveira NB; Shannon CM; Tinker AV; Gilks CB; Coward JI; Lumley JW; Perrin LC; Armes JE; Hooper JD
Oncogene; 2016 Jan; 35(4):468-78. PubMed ID: 25893298
[TBL] [Abstract][Full Text] [Related]
17. Dysregulated expression of cell surface glycoprotein CDCP1 in prostate cancer.
Yang L; Dutta SM; Troyer DA; Lin JB; Lance RA; Nyalwidhe JO; Drake RR; Semmes OJ
Oncotarget; 2015 Dec; 6(41):43743-58. PubMed ID: 26497208
[TBL] [Abstract][Full Text] [Related]
18. EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface.
Adams MN; Harrington BS; He Y; Davies CM; Wallace SJ; Chetty NP; Crandon AJ; Oliveira NB; Shannon CM; Coward JI; Lumley JW; Perrin LC; Armes JE; Hooper JD
Oncogene; 2015 Mar; 34(11):1375-83. PubMed ID: 24681947
[TBL] [Abstract][Full Text] [Related]
19. [Effect of HIF-2α on regulating CDCP1 to promote hepatocellular carcinoma metastasis].
Cao MQ; Gao JR; Huang JF; You AB; Guo ZG; Zhou HY; Fang F; Zhang W; Zhu XL; Zhang T
Zhonghua Zhong Liu Za Zhi; 2017 Jan; 39(1):18-23. PubMed ID: 28104028
[No Abstract] [Full Text] [Related]
20. Antibody mediated CDCP1 degradation as mode of action for cancer targeted therapy.
Kollmorgen G; Niederfellner G; Lifke A; Spohn GJ; Rieder N; Harring SV; Bauss F; Burtscher H; Lammers R; Bossenmaier B
Mol Oncol; 2013 Dec; 7(6):1142-51. PubMed ID: 24055141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
